Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers

20200107 PR TG4050 FPI – EN

Published 7 January 2020
Categorized as 2020, Press release, TG4050

Transgene Announces Financial Calendar for 2020

20191218 Financial calendar 2020 EN

Published 18 December 2019
Categorized as 2019, Press release

Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer

20191212 PR TG4010_EN_results

Published 12 December 2019
Categorized as 2019, Press release, TG4010

Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors

20191211 PR preclinical BT001 EN

Published 11 December 2019
Categorized as 2019, BT-001, Invir.IO, Press release

Transgene Announces Investor Meetings for January 2020

20191209 PR Investors Meeting agenda 2020

Published 9 December 2019
Categorized as 2019, Press release

Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001

20191114 Résultats T3-2019 EN

Published 14 November 2019
Categorized as 2019, Press release

Transgene Will Participate in the Jefferies 2019 London Healthcare Conference

20191022 – Transgene PR Jefferies EN

Published 22 October 2019
Categorized as 2019, Press release

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

20190930 PR TG4001 ESMO EN

Published 30 September 2019
Categorized as 2019, Press release, TG4001, TG4001

Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results

20190918-Transgene-H1-2019-RESULTS-EN

Published 18 September 2019
Categorized as 2019, Press release

Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050

20190916 PR ANSM TG4050 EN

Published 16 September 2019
Categorized as 2019, Myvac, Press release, TG4050

Posts pagination

Newer posts Page 1 … Page 20 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu